Androgen replacement therapy for cancer‐related symptoms in male: result of prospective randomized trial (ARTFORM study)

by Kouji Izumi, Hiroaki Iwamoto, Hiroshi Yaegashi, Takahiro Nohara, Kazuyoshi Shigehara, Yoshifumi Kadono, Shigeki Nanjo, Tadaaki Yamada, Koshiro Ohtsubo, Seiji Yano, Atsushi Mizokami
Published 2021-08-01

Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.

by Shigeki Nanjo, Tadaaki Yamada, Hiroshi Nishihara, Shinji Takeuchi, Takako Sano, Takayuki Nakagawa, Daisuke Ishikawa, Lu Zhao, Hiromichi Ebi, Kazuo Yasumoto, Kunio Matsumoto, Seiji Yano
Published 2013-01-01

mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.

by Daisuke Ishikawa, Shinji Takeuchi, Takayuki Nakagawa, Takako Sano, Junya Nakade, Shigeki Nanjo, Tadaaki Yamada, Hiromichi Ebi, Lu Zhao, Kazuo Yasumoto, Takahiro Nakamura, Kunio Matsumoto, Hiroshi Kagamu, Hirohisa Yoshizawa, Seiji Yano
Published 2013-01-01